Literature DB >> 21540163

Primary hyperparathyroidism.

Hafsah Al-Azem1, Aliya Khan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21540163      PMCID： PMC3134760          DOI： 10.1503/cmaj.090675

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  15 in total

Review 1.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

2.  Hyperfunctioning parathyroid tissue: spectrum of appearances on noninvasive imaging.

Authors:  Michael B Gotway; Jessica W T Leung; Gretchen A Gooding; Harold I Litt; Gautham P Reddy; Eugene T Morita; W Richard Webb; Orlo H Clark; Charles B Higgins
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

3.  The diagnosis and management of asymptomatic primary hyperparathyroidism revisited.

Authors:  Aliya A Khan; John P Bilezikian; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

Review 4.  Familial benign hypocalciuric hypercalcemia.

Authors:  Ghada El-Hajj Fuleihan
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

Review 5.  Clinical review: Rare causes of hypercalcemia.

Authors:  Thomas P Jacobs; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

6.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

7.  Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.

Authors:  Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

8.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors:  Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

9.  Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Canada: Consensus Development Task Force on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism position paper.

Authors: 
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

Review 10.  Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  R Eastell; A Arnold; M L Brandi; E M Brown; P D'Amour; D A Hanley; D Sudhaker Rao; M R Rubin; D Goltzman; S J Silverberg; S J Marx; M Peacock; L Mosekilde; R Bouillon; E M Lewiecki
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958
View more
  2 in total

Review 1.  The association of primary hyperparathyroidism with pancreatitis.

Authors:  Harrison X Bai; Matthew Giefer; Mohini Patel; Abrahim I Orabi; Sohail Z Husain
Journal:  J Clin Gastroenterol       Date:  2012-09       Impact factor: 3.062

2.  An unusual case of malignancy-related hypercalcemia.

Authors:  Mary-Anne Doyle; Janine C Malcolm
Journal:  Int J Gen Med       Date:  2013-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.